The tricyclic oxazolidines trans-4 and cis-4 were interconverted upon treatment with allyltrimethylsilane/TiCl 4 . The oxazolidine trans-4 was diastereoselectively reacted with PhMgBr to yield the 4,4-disubstituted 3-benzazepinone 6, along with two side products. An X-ray crystal structure analysis of 6 proved the (R)-configuration of the stereogenic center C-4 and thus the retention of configuration. Reduction of 6 with AlCl 3 /LiAlH 4 (1/3) followed by hydrogenolysis with H 2 , Pd/C resulted in the formation of enantiomerically pure 2-methyl-2-phenyl-tetrahydro-3-benzazepine 11 which has a moderate affinity (K i = 496 nM) to the PCP binding site of the NMDA receptor.
Introduction
The NMDA receptor belongs to the group of ionotropic glutamate receptors and is activated by Nmethyl-D-aspartate (NMDA). The ionotropic glutamate receptors have in common substantial permeability to both Na + and K + ions but differ in permeability to Ca 2+ ions. The NMDA receptor plays a fundamental role in excitatory neurotransmission in the central nervous system (CNS) and affects plasticity, memory and learning, in addition to neuronal development. The target of this project is specifically the phencyclidine (PCP) binding site, which is located within the NMDA receptor-associated ion channel. Ligands interacting with the PCP binding site block the influx of Ca 2+ ions and therefore function as NMDA receptor antagonists [1, 2] .
Modulators of glutamate receptors have been the subject of intense research since they can be used for the treatment of a wide variety of conditions, ranging from acute ischemia and trauma, to chronic neurodegenerative disorders such as Huntington's, Parkinson's and Alzheimer's diseases, epilepsy, and HIV-associated dementia (HAD). Moreover, even psychiatric disorders have been proposed to be amenable to glutamatergic modulation [3, 4] . 0932 -0776 / 10 / 0200-0191 $ 06.00 c 2010 Verlag der Zeitschrift für Naturforschung, Tübingen · http://znaturforsch.com The tetracyclic amine MK-801 (1) is a very potent non-competitive NMDA receptor antagonist (K i = 2.6 nM), which acts as an open channel blocker ( Fig. 1 ) [1, 4] . The formal cleavage of the C 9a -C 10 bond of MK-801 results in tetrahydroisoquinolines 2, which also interact with the PCP binding site. The NMDA receptor affinities of the enantiomeric isoquinolines (R)-2 and (S)-2 differ considerably with (S)-2 showing high (K i = 35.4 nM) and (R)-2 low affinity (K i = 3.76 µ M) [5] .
In this work we aimed at synthesizing 2,2-disubstituted tetrahydro-3-benzazepines 3 with an additional methylene moiety in the heterocyclic ring system when compared with the isoquinolines 2. In particular, tetrahydro-3-benzazepines 3 with the same configuration at the C-2 stereocenter as the more potent enantiomer (S)-2 should be synthesized in order to get novel ligands with high affinity towards the PCP binding site of the NMDA receptor.
The C-2 stereocenter of 3 should be established by stereoselective opening of the oxazolidines trans-4 and cis-4 with carbon nucleophiles. The stereodescriptors cis and trans define the relative configuration of the higher ordered phenyl and benzyl residues or the lower ordered proton and methyl moiety in the oxazolidine ring [9] . In the literature [6] , the opening of an oxazolidine ring in a bicyclic system with two substituents at the N/O-ketalic stereocenter by carbon nucleophiles has not been reported so far.
Results
The key intermediates trans-4 and cis-4 were prepared by heating of 2-[2-(2-oxopropyl)phenyl]acetic acid [7] with (R)-phenylglycinol in toluene [8] .
At first the stereoselective introduction of an allyl nucleophile at the N/O-ketalic stereocenter in position 11a was investigated (Scheme 1). For this purpose, trans-4 was reacted with allyltrimethylsilane (2 equiv.) and TiCl 4 (1 equiv.). Only very low amounts of the desired 4,4-disubstituted tetrahydro-3-benzazepine 5 were detected by 1 the low yield, the allyl derivative 5 could not be isolated.
This observation prompted us to study the interconversion reaction in more detail. Very recently we have shown that p-toluenesulfonic acid and trifluoroacetic acid are not able to isomerize the diastereomers trans-4 and cis-4 [8, 9] . Treatment of both diastereomers trans-4 and cis-4 with TiCl 4 , allyltrimethylsilane or triethylsilane alone also did not lead to any interconversion. However, the reaction of the diastereomer cis-4 with allyltrimethylsilane (2 equiv.) and TiCl 4 (1 equiv.) led to isomerization, but without formation of any substitution product (trans-4 : cis-4 = 11 : 89). Obviously, both TiCl 4 and a silane are required for this isomerization.
Since further products were not formed along with cis-4, the isomerization reaction was further investigated using cis-4 only. Prolongation of the reaction time from 1 to 3 d led to a ratio of trans-4 : cis-4 of 38 : 62. Work-up of this mixture provided the diastereomer trans-4 in 35 % isolated yield. This isomerization process allows the increase of the yield of the desired stereoisomer and thus represents a considerable improvement of the asymmetric synthesis of tetrahydro-3-benzazepines using tricyclic oxazolidines of type 4, because the synthesis of 4 always affords 1 : 1 mixtures of cis and trans diastereomers [8, 9] .
In order to introduce carbon nucleophiles into the tetrahydro-3-benzazepine scaffold, Grignard reagents were tried [10] . For this purpose the tricyclic oxazolidine trans-4 was reacted with 3 equivalents of PhMgBr in THF at 0 • C (Scheme 2). This transformation led to the 4,4-disubstituted tetrahydro-3-benzazepine 6 along with two side products, 7 and 8, which were separated by flash chromatography. The elimination product 7 was isolated in 17 % yield and represented the major product. The yield of the hydroxylated product 8 (only one diastereomer) was 7.5 %, whereas the desired tetrahydro-3-benzazepine derivative 6 was obtained in only 6.5 % yield.
In order to prove the configuration of the 4,4-disubstituted tetrahydro-3-benzazepine derivative 6, an X-ray crystal structure analysis was performed (Fig. 2) . Suitable crystals were obtained by recrystallization from an n-hexane/CH 2 Cl 2 mixture. The crystal structure of 6 clearly shows the (R)-configuration in position 4 indicating that the nucleophilic attack had taken place with retention of configuration.
The formation of products 6 and 7 can be explained by coordination of the magnesium atom of the Grig-Scheme 2. Reaction of trans-4 with three equivalents of PhMgBr and transformation of 6 into the enantiomerically pure 2,2-disubstituted tetrahydro-3-benzazepine 11. nard reagent with the oxygen atom of the oxazolidine moiety as shown in intermediate 9 (Scheme 3) [10] . After coordination, the Ph group of PhMgBr can act as a nucleophile as well as a base. The delivery of the phenyl nucleophile from the same face as the C-O bond results in the 4,4-disubstituted tetrahydro-3-benzazepine 6 and accounts for the observed retention of configuration. In addition to the nucleophilic attack, the coordinated phenyl moiety is able to remove a proton from the methyl moiety via a six-membered ring transition state. Subsequent oxazolidine ring opening Table 1 . Affinity of the 2,2-disubstituted tetrahydro-3-benzazepine 11 towards NMDA, σ 1 and σ 2 receptors.
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yields the 4-methylene-substituted tetrahydro-3-benzazepine derivative 7. This side reaction together with the sterically demanding N/O-ketalic substructure is responsible for the low yields of the desired product 6. Next, cis-4 was reacted with 3 equivalents of PhMgBr. This reaction did not provide a 4,4-disubstituted or a 4-methylene-substituted tetrahydro-3-benzazepine derivative like 6 or 7. We assume that in the case of cis-configuration both faces of the oxazolidine plane are shielded by the phenyl moiety in position 3 (above the ring plane) and the C-11a methyl moiety (below the ring plane). Therefore, coordination of PhMgBr with the oxazolidine ring O atom is inhibited resulting in fast deprotonation in α-position of the lactame carbonyl moiety [11] .
The 4,4-disubstituted tetrahydro-3-benzazepine derivative 6 was used to synthesize the enantiomerically pure 2,2-disubstituted tetrahydro-3-benzazepine 11 (Scheme 2). In the first step, the lactame 6 was reduced with AlH 3 , which had been formed in situ by mixing AlCl 3 and LiAlH 4 in the ratio 1 : 3 [12] , to obtain the N-substituted tetrahydro-3-benzazepine 10 in 69 % yield. Finally, the N-(2-hydroxy-1-phenylethyl) protective group of 10 was removed by hydrogenolysis (H 2 , Pd/C) to provide (2R)-11 in 67 % yield.
In competitive receptor binding studies with radioligands [13] , the (R)-2-methyl-2-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine 11 revealed moderate affinity towards the PCP binding site of the NMDA receptor (K i = 496 nM, Table 1 ). Compared with the smaller homologous isoquinoline (S)-2 [5] , which has the same stereochemistry as 11 [14] , the affinity is about 10-fold reduced. Obviously, increasing of the ring size by one methylene moiety results in lowering of binding at the PCP binding site of the NMDA receptor.
In addition to the NMDA receptor affinity the affinity of the tetrahydro-3-benzazepine 11 towards σ 1 and σ 2 receptors was investigated [15] . The compound did not show any significant affinity to σ 1 receptors (K i > 2000 nM). However, a surprisingly high σ 2 receptor affinity (K i = 134 nM) was observed, which even exceeds the NMDA receptor affinity. Nevertheless, 11 represents the starting point for the development of novel potent NMDA receptor antagonists and σ 2 receptor ligands.
In conclusion a method for the interconversion of the diastereomeric tricyclic oxazolidines trans-4 and cis-4 has been developed, which increases the overall yield of the desired diastereomer for subsequent asymmetric syntheses. Whereas the oxazolidine trans-4 reacted with phenylmagnesium bromide to form the 4,4-disubstituted tetrahydro-3-benzazepine 6, the corresponding cis-4 did not react to form a phenyl addition product. Compound 6 was transformed into the (R)-2-methyl-2-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine 11, which revealed promising affinity to the PCP binding site of the NMDA receptor and the σ 2 receptor.
Experimental Section

General
Unless otherwise mentioned, THF was dried with sodium/benzophenone and was freshly distilled before use. 
Conversion of cis-4 into trans-4
Under an atmosphere of N 2 a solution of TiCl 4 (4.5 mL of 1.0 M in CH 2 Cl 2 ; 4.5 mmol, 1 equiv.) was added via syringe to a stirred solution of allyltrimethylsilane (0.73 mL, 9.0 mmol, 2 equiv.) and oxazolidine cis-4 (1.32 mg, 4.5 mmol) in dry CH 2 Cl 2 (24 mL) at r. t. The resulting solution was stirred at r. t. for 3 d. Then it was cooled to 0 • C and carefully quenched with saturated aqueous ammonium chloride (20 mL). The resulting mixture was diluted with water (10 mL) and extracted with CH 2 Cl 2 (3 × 20 mL). The combined organic layers were washed with saturated aqueous NaHCO 3 (15 mL) and brine (15 mL), dried (Na 2 SO 4 ), and concentrated in vacuo to give 1.56 g of the crude product. The product was purified by fc (3 cm, 1 = 20 cm, EtOAc/cyclohexane 10/90 to 40/60, 25 mL). trans-4 (R f = 0.48, EtOAc/petroleum ether 50/50) and cis-4 (R f = 0.14, EtOAc/petroleum ether 50/50) were isolated as colorless solids [9] in yields of 462 mg (35 %) and 713 mg (54 %), respectively.
(4R)-3-[(1R)-2-Hydroxy-1-phenylethyl]-4-methyl-4-phenyl-1,3,4,5-tetrahydro-3-benzazepin-2-one (6), 3-[(1R)-2-hydroxy-1-phenylethyl]-4-methylene-1,3,4,5-tetrahydro-3-benzazepin-2-one (7) and 1-hydroxy-3-[(1R)-2-hydroxy-1-phenylethyl]-4-methylene-1,3,4,5-tetrahydro-3-benzazepin-2-one (8)
A solution of trans-4 (405 mg, 1.38 mmol) in THF (24 mL) was added via cannula to a solution of PhMgBr (1.0 M in THF, 4.14 mmol) at 0 • C, and the mixture was stirred at this temperature for 10 h and then at r. t. for 8 h. The reaction was quenched by addition of a saturated NaCl solution, and the mixture was extracted with EtOAc (3 × 15 mL). The combined organic extracts were dried (Na 2 SO 4 ) and concentrated in vacuum. The residue (520 mg) was purified by fc (2 cm, 1 = 20 cm, EtOAc/cyclohexane 20/80 to 35/65, 15 mL).
6: R f = 0.14, (EtOAc/cyclohexane 40/60), colorless solid, yield 27 mg (6 %). 12 (m, 7H, arom. CH), 7.19 -7.34 (m, 4H, arom. CH) . 
(2R)-2-[(2R)-2-Methyl-2-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepin-3-yl]-2-phenylethanol (10)
Under N 2 at 0 • C dry THF (2mL) was added to anhydrous AlCl 3 (7.8 mg, 0.059 mmol, 1 equiv.) and stirred for 5 min. Then a solution of LiAlH 4 (0.17 mL, 1.0 M in THF, 0.177 mmol; 3 equiv.) was added via syringe. The resulting clear, colorless solution was allowed to warm to r. t. and was stirred for 20 min to give a solution of alane (AlH 3 ). A solution of 6 (22 mg, 0.059 mmol) in dry THF (2 mL) was added at 0 • C. The resulting solution was stirred at 0 • C for 3 h and then warmed to r. t. over 30 min. The resulting clear solution was cooled to 0 • C and then quenched by careful addition of 1 M HCl (only few drops). The resulting slurry was diluted with water (10 mL) and extracted with CH 2 Cl 2 (3 × 5 mL). The combined organic layers were washed with 1 M NaOH and brine (10 mL 
(2R)-2-Methyl-2-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine (11)
A mixture of 10 (13 mg, 0.036 mmol) and Pd/C (10 % by wt) in methanol (1.5 mL) and 1 M HCl (0.5 mL) was stirred at r. t. under an H 2 atmosphere (balloon) for 6 h. The reaction mixture was filtered using a silica gel bed, and the solvent was removed under reduced pressure to obtain a residue, which was dissolved in CH 2 Cl 2 (10 mL) and washed with 1 M NaOH (3 × 4 mL). The combined organic layers were dried (Na 2 SO 4 ), filtered and concentrated in vacuo to provide an oil (10 mg); fc (1 cm, 1 = 20 cm, EtOAc/petroleum ether/NH 3 40/59.5/0.5, 10 mL, R f = 0.33). Colorless liquid, yield 5.8 mg (67 %). 
